In JAMA Network Open, researchers from Radboud University Medical Center and elsewhere share results suggesting routine molecular profiling beyond Lynch syndrome screening may not improve outcomes for individuals with low-grade endometrial cancer — a condition that appeared to have favorable prognoses across its known molecular subtypes. Using next-generation sequence- and immunohistochemistry-based profiles, the team retrospectively classified almost 400 endometrial cases diagnosed in Europe from the mid-1990s through 2018 into four molecular subgroups: POLE-altered, microsatellite instable, TP53-altered, or no specific molecular profile. While five-year survival tended to be lower in patients with high-grade, TP53-altered, stage III or IV endometrial cancer, the authors found, low-grade endometrial cancer cases had favorable five-year survival patterns across the molecular subtypes considered. "The findings of this cohort study suggest that routine molecular profiling would not be beneficial in patients with low-grade [endometrial cancer] due to their excellent prognosis independent of molecular subgroup," they write. "Our data demonstrate the importance of primary diagnostic tumor grading and do not support routine molecular profiling in low-grade [endometrial cancer] as a cost-effective approach."
Retrospective Analysis Suggests Molecular Profiling Often Not Beneficial in Low-Grade Endometrial Cancer
Dec 19, 2022